SE0201713D0 - New methods and use III - Google Patents
New methods and use IIIInfo
- Publication number
- SE0201713D0 SE0201713D0 SE0201713A SE0201713A SE0201713D0 SE 0201713 D0 SE0201713 D0 SE 0201713D0 SE 0201713 A SE0201713 A SE 0201713A SE 0201713 A SE0201713 A SE 0201713A SE 0201713 D0 SE0201713 D0 SE 0201713D0
- Authority
- SE
- Sweden
- Prior art keywords
- glutamate
- vertebrate
- bird
- including mammal
- new methods
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 abstract 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 4
- 150000002306 glutamic acid derivatives Chemical class 0.000 abstract 4
- 210000000988 bone and bone Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201713A SE0201713D0 (sv) | 2001-11-23 | 2002-06-06 | New methods and use III |
BR0214364-0A BR0214364A (pt) | 2001-11-23 | 2002-11-22 | Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado |
CNB028245253A CN100531731C (zh) | 2001-11-23 | 2002-11-22 | 谷氨酸盐、谷氨酸盐衍生物或代谢产物、谷氨酸盐类似物或其混合物在制备治疗骨质疏松症的组合物中的用途 |
DK02791128.8T DK1446112T3 (da) | 2001-11-23 | 2002-11-22 | Anvendelse af glutamat, glutamatderivater eller metabolitter, glutamatanaloger eller blandinger deraf til fremstilling af en sammensætning til behandling af osteoporose |
CA2467676A CA2467676C (fr) | 2001-11-23 | 2002-11-22 | Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose |
KR1020047007846A KR100961291B1 (ko) | 2001-11-23 | 2002-11-22 | 골다공증 치료용 조성물의 제조에 사용되는 글루타메이트,글루타메이트 유도체 또는 대사산물, 글루타메이트 유사체또는 이들의 혼합물의 용도 |
US10/496,350 US8603981B2 (en) | 2001-11-23 | 2002-11-22 | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
EP02791128.8A EP1446112B1 (fr) | 2001-11-23 | 2002-11-22 | Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose |
JP2003545307A JP4447913B2 (ja) | 2001-11-23 | 2002-11-22 | オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用 |
AU2002366111A AU2002366111B2 (en) | 2001-11-23 | 2002-11-22 | Use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
MXPA04004904A MXPA04004904A (es) | 2001-11-23 | 2002-11-22 | Uso de glutamato, derivados o metabolitos de glutamato, analogos de glutamato o mezclas de los mismos para la preparacion de una composicion para el tratamiento de osteoporosis. |
PCT/SE2002/002123 WO2003043626A1 (fr) | 2001-11-23 | 2002-11-22 | Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose |
ES02791128T ES2431085T3 (es) | 2001-11-23 | 2002-11-22 | Uso de glutamato, derivados o metabolitos de glutamato, análogos de glutamato o mezclas de los mismos para la fabricación de una composición para el tratamiento de osteoporosis |
PT2791128T PT1446112E (pt) | 2001-11-23 | 2002-11-22 | Utilização de glutamato, derivados ou metabolitos de glutamato, análogos de glutamato ou misturas dos mesmos para o fabrico de uma composição para o tratamento da osteoporose |
HK05101425.8A HK1071059A1 (en) | 2001-11-23 | 2005-02-18 | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
US14/101,234 US9233088B2 (en) | 2001-11-23 | 2013-12-09 | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0103932 | 2001-11-23 | ||
SE0104385A SE520842C2 (sv) | 2001-11-23 | 2001-12-21 | Användning av glutamat, glutamatderivat, glutamatmetaboliter eller glutamatanaloger för att framställa en sammansättning för behandling av osteoporos |
SE0201713A SE0201713D0 (sv) | 2001-11-23 | 2002-06-06 | New methods and use III |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0201713D0 true SE0201713D0 (sv) | 2002-06-06 |
Family
ID=27354772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0201713A SE0201713D0 (sv) | 2001-11-23 | 2002-06-06 | New methods and use III |
Country Status (15)
Country | Link |
---|---|
US (2) | US8603981B2 (fr) |
EP (1) | EP1446112B1 (fr) |
JP (1) | JP4447913B2 (fr) |
KR (1) | KR100961291B1 (fr) |
CN (1) | CN100531731C (fr) |
AU (1) | AU2002366111B2 (fr) |
BR (1) | BR0214364A (fr) |
CA (1) | CA2467676C (fr) |
DK (1) | DK1446112T3 (fr) |
ES (1) | ES2431085T3 (fr) |
HK (1) | HK1071059A1 (fr) |
MX (1) | MXPA04004904A (fr) |
PT (1) | PT1446112E (fr) |
SE (1) | SE0201713D0 (fr) |
WO (1) | WO2003043626A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005082385A1 (fr) | 2004-02-26 | 2005-09-09 | Osteologix A/S | Composes a base de strontium destines a etre utilises dans la prevention ou le traitement de conditions d'os necrotiques |
PL1745791T3 (pl) | 2003-05-07 | 2013-11-29 | Osteologix As | Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu |
MXPA05013901A (es) * | 2003-07-01 | 2006-03-09 | Essentys Ab | Uso de acido alfa-cetoglutarico para tratamiento de desnutricion o condicion de glucosa alta en plasma. |
SE0301947D0 (sv) * | 2003-07-01 | 2003-07-01 | Gramineer Internat Ab | New method and uses |
US7335686B2 (en) * | 2003-10-20 | 2008-02-26 | Council Of Scientific And Industrial Research | Method and composition for treating osteoporosis |
PL368573A1 (en) * | 2004-06-17 | 2005-12-27 | Sgp & Sons Ab | Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals |
PL370937A1 (pl) * | 2004-10-29 | 2006-05-02 | Sgp & Sons Ab | Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi |
PL371081A1 (pl) * | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
US20110105617A1 (en) * | 2005-01-11 | 2011-05-05 | Sgp & Sons Ab | Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof |
PL372183A1 (pl) * | 2005-01-11 | 2006-07-24 | Sgp & Sons Ab | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
WO2007058612A1 (fr) * | 2005-11-15 | 2007-05-24 | Entress Ab | Medicament a utiliser en rapport avec la deterioration de cartilage |
SG194028A1 (en) * | 2011-04-18 | 2013-11-29 | Nestec Sa | Nutritional compositions having alpha-hica and eicosapentaenoic acid |
EP2782588B1 (fr) * | 2011-11-21 | 2020-04-15 | Emmaus Medical, Inc. | Procédés et compositions pour le traitement du diabète et de symptômes associés |
CN102805857B (zh) * | 2012-08-27 | 2014-07-02 | 北京紫萌同达科技有限公司 | 一种复方氨基酸(15)双肽(2)注射液的制备方法 |
CN105231038A (zh) * | 2015-09-23 | 2016-01-13 | 华南农业大学 | α-酮戊二酸在制备猪饲料添加剂方面的应用 |
EP3490971A4 (fr) * | 2016-08-01 | 2020-02-26 | Filament Biosolutions Inc. | Méthodes de traitement et de prévention des effets secondaires du traitement du cancer |
CN110935005A (zh) * | 2019-11-19 | 2020-03-31 | 宁波大学 | 一种丙谷二肽的新用途 |
CN111820330A (zh) * | 2020-07-17 | 2020-10-27 | 禹城保立康生物饲料有限公司 | 一种提高哺乳仔猪发育的母猪饲料 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668295A (en) * | 1985-04-25 | 1987-05-26 | University Of Dayton | Surgical cements |
US5310768A (en) * | 1987-10-29 | 1994-05-10 | Ab Erik Vinnars | Method for improving the glutamine content in skeletal muscle and composition therefore |
JPH01216924A (ja) | 1988-02-24 | 1989-08-30 | Ajinomoto Co Inc | 肝障害治療剤 |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
JPH04164028A (ja) | 1990-02-19 | 1992-06-09 | Miwon Co Ltd | グルタミン酸モノナトリウムを主成分とする疲労快復剤およびその使用方法 |
JP2702322B2 (ja) * | 1991-08-08 | 1998-01-21 | フジックス株式会社 | 活性アミノ酸カルシウム、およびそれを含有する飲料、ならびにその製造方法 |
JP3551149B2 (ja) * | 1992-03-24 | 2004-08-04 | 味の素株式会社 | 易吸収性ミネラル含有組成物及びそれを含有する飲食品 |
US5646187A (en) * | 1992-05-20 | 1997-07-08 | Ab Erik Vinnars | Use of alpha-ketoglutarate |
JP2964290B2 (ja) | 1992-08-25 | 1999-10-18 | 雪印乳業株式会社 | ミネラル吸収促進剤 |
US5380934A (en) | 1992-10-29 | 1995-01-10 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing alanylgutamine |
DE69330595T2 (de) | 1992-11-25 | 2002-05-23 | Ajinomoto Co., Inc. | Zubereitungen und Nahrungsmittel enthaltend Mineralien und Poly-gamma-Glutaminsäure |
US5849695A (en) * | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
SE9303691D0 (sv) | 1993-11-09 | 1993-11-09 | Gramineer Ab | New beverage |
CN1060336C (zh) * | 1995-12-05 | 2001-01-10 | 孔彦平 | 一种防治钙质缺损的药物及其制备方法 |
US5817329A (en) * | 1997-02-28 | 1998-10-06 | Gardiner; Paul T. | Nutritional supplement for increased muscle size and strength for body builders |
NL1014380C2 (nl) | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
-
2002
- 2002-06-06 SE SE0201713A patent/SE0201713D0/xx unknown
- 2002-11-22 PT PT2791128T patent/PT1446112E/pt unknown
- 2002-11-22 KR KR1020047007846A patent/KR100961291B1/ko not_active IP Right Cessation
- 2002-11-22 JP JP2003545307A patent/JP4447913B2/ja not_active Expired - Fee Related
- 2002-11-22 MX MXPA04004904A patent/MXPA04004904A/es active IP Right Grant
- 2002-11-22 BR BR0214364-0A patent/BR0214364A/pt not_active IP Right Cessation
- 2002-11-22 AU AU2002366111A patent/AU2002366111B2/en not_active Ceased
- 2002-11-22 US US10/496,350 patent/US8603981B2/en not_active Expired - Fee Related
- 2002-11-22 ES ES02791128T patent/ES2431085T3/es not_active Expired - Lifetime
- 2002-11-22 CA CA2467676A patent/CA2467676C/fr not_active Expired - Fee Related
- 2002-11-22 EP EP02791128.8A patent/EP1446112B1/fr not_active Expired - Lifetime
- 2002-11-22 CN CNB028245253A patent/CN100531731C/zh not_active Expired - Fee Related
- 2002-11-22 DK DK02791128.8T patent/DK1446112T3/da active
- 2002-11-22 WO PCT/SE2002/002123 patent/WO2003043626A1/fr active IP Right Grant
-
2005
- 2005-02-18 HK HK05101425.8A patent/HK1071059A1/xx not_active IP Right Cessation
-
2013
- 2013-12-09 US US14/101,234 patent/US9233088B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2003043626A1 (fr) | 2003-05-30 |
US8603981B2 (en) | 2013-12-10 |
CA2467676A1 (fr) | 2003-05-30 |
MXPA04004904A (es) | 2005-04-11 |
KR20050044589A (ko) | 2005-05-12 |
JP4447913B2 (ja) | 2010-04-07 |
ES2431085T3 (es) | 2013-11-25 |
PT1446112E (pt) | 2013-10-21 |
AU2002366111B2 (en) | 2007-06-28 |
EP1446112A1 (fr) | 2004-08-18 |
CN1602190A (zh) | 2005-03-30 |
US9233088B2 (en) | 2016-01-12 |
KR100961291B1 (ko) | 2010-06-04 |
CN100531731C (zh) | 2009-08-26 |
US20040259766A1 (en) | 2004-12-23 |
US20140194521A1 (en) | 2014-07-10 |
ES2431085T8 (es) | 2014-01-03 |
AU2002366111A1 (en) | 2003-06-10 |
BR0214364A (pt) | 2004-10-26 |
CA2467676C (fr) | 2011-07-12 |
DK1446112T3 (da) | 2013-10-07 |
AU2002366111B8 (en) | 2003-06-10 |
JP2005518353A (ja) | 2005-06-23 |
HK1071059A1 (en) | 2005-07-08 |
EP1446112B1 (fr) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0201713D0 (sv) | New methods and use III | |
ATE322258T1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
NO20025590D0 (no) | Fenylglycin-derivater | |
DE60327089D1 (de) | Systeme zum verschieben und/oder zurückhalten von gewebe in den oberen atemwegen | |
BG106013A (en) | New compounds and compositions as protease inhibitors | |
DK1638586T3 (da) | Synergistisk sammensætning til behandling af diabetes mellitus | |
HK1095138A1 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
GEP20084488B (en) | Use of therapeutic agents for treating pain | |
CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
IL175158A0 (en) | Tocopherol-modified therapeutic drug compounds | |
DE60036169D1 (de) | Methoden zur Behandlung der Hautpigmentierung | |
MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
ATE495187T1 (de) | Dalda-analoge und ihre verwendung | |
ATE301995T1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
DE60108857D1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
SE9803760D0 (sv) | Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel | |
GB2352972A (en) | Use of dexmedetomidine for icu sedation | |
SE0203303D0 (sv) | Novel Compounds | |
ATE422892T1 (de) | Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle | |
WO2005062992A3 (fr) | Derives substitues de melatonine, procede de fabrication et methodes d'utilisation | |
MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
SE0301947D0 (sv) | New method and uses | |
BR0309747A (pt) | Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial |